STOCK TITAN
  1. Home
  2. Sec-filings
  3. AORT
  4. [Form 4] ARTIVION, INC. Insider Trading Activity

Artivion SVP Marshall Stanton reports option exercises and sales

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Artivion, Inc. (AORT) senior vice president Marshall Stanton reported multiple stock option exercises and related share sales dated 11/21/2025. He exercised options to buy 20,301 shares of common stock at $18.44 per share and another 27,075 shares at $11.03 per share. On the same date, he sold blocks of 14,586 shares at a weighted average price of $44.919, 5,715 shares at $45.346, 18,705 shares at $44.91, and 8,370 shares at $45.345, with each price representing a weighted average within disclosed ranges. After these transactions, he directly owned 44,753 shares of Artivion common stock.

Positive

  • None.

Negative

  • None.
Insider Stanton Marshall S.
Role SVP, Clinical & MD Affair
Sold 47,376 shs ($2.13M)
Type Security Shares Price Value
Exercise Stock Options (Right to buy) 20,301 $0.00 --
Exercise Stock Options (Right to buy) 27,075 $0.00 --
Exercise Common Stock 20,301 $18.44 $374K
Sale Common Stock 14,586 $44.919 $655K
Sale Common Stock 5,715 $45.346 $259K
Exercise Common Stock 27,075 $11.03 $299K
Sale Common Stock 18,705 $44.91 $840K
Sale Common Stock 8,370 $45.345 $380K
Holdings After Transaction: Stock Options (Right to buy) — 0 shares (Direct); Common Stock — 65,054 shares (Direct)
Footnotes (1)
  1. Reflects weighted average price. Range of prices were between $44.26 to $45.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Reflects weighted average price. Range of prices were between $45.26 to $45.54. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Reflects weighted average price. Range of prices were between $44.26 to $45.255. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Reflects weighted average price. Range of prices were between $45.26 to $45.53. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stanton Marshall S.
(Last) (First) (Middle)
1655 ROBERTS BLVD., NW
(Street)
KENNESAW GA 30144
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Clinical & MD Affair
3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/21/2025 M 20,301 A $18.44 65,054 D
Common Stock 11/21/2025 S 14,586 D $44.919(1) 50,468 D
Common Stock 11/21/2025 S 5,715 D $45.346(2) 44,753 D
Common Stock 11/21/2025 M 27,075 A $11.03 71,828 D
Common Stock 11/21/2025 S 18,705 D $44.91(3) 53,123 D
Common Stock 11/21/2025 S 8,370 D $45.345(4) 44,753 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to buy) $18.44 11/21/2025 M 20,301 02/23/2023(5) 02/23/2029 Common Stock 20,301 $0 0 D
Stock Options (Right to buy) $11.03 11/21/2025 M 27,075 11/08/2023(6) 11/08/2029 Common Stock 27,075 $0 0 D
Explanation of Responses:
1. Reflects weighted average price. Range of prices were between $44.26 to $45.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
2. Reflects weighted average price. Range of prices were between $45.26 to $45.54. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
3. Reflects weighted average price. Range of prices were between $44.26 to $45.255. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
4. Reflects weighted average price. Range of prices were between $45.26 to $45.53. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
5. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023.
6. Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023.
Remarks:
/s/ Marshall Stanton 11/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Artivion (AORT) report on this Form 4?

The filing reports that officer Marshall Stanton exercised stock options and sold Artivion common shares on 11/21/2025, updating his direct ownership.

How many Artivion (AORT) stock options did the insider exercise?

He exercised options to acquire 20,301 shares at an exercise price of $18.44 and 27,075 shares at $11.03 per share.

How many Artivion (AORT) shares did the insider sell and at what prices?

On 11/21/2025, he sold blocks of 14,586, 5,715, 18,705, and 8,370 shares at weighted average prices of about $44.9–$45.35 per share, each within stated price ranges.

What is the insider’s remaining ownership in Artivion (AORT) after these trades?

Following the reported transactions, the filing states that he directly owned 44,753 shares of Artivion common stock.

What is the insider’s role and relationship to Artivion (AORT)?

The reporting person is listed as an officer of Artivion, Inc., serving as SVP, Clinical & MD Affair, and the Form 4 is filed for one reporting person.

How do the weighted average prices work in this Artivion (AORT) Form 4?

For each sale line, the price shown is a weighted average, and the filing notes that the full breakdown of share counts at each price within the disclosed ranges is available upon request.